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Opa b s t r a c t
Objective: The aim of this study was to investigate the impact of hypoglycemia according to severity and
time of onset on health-related quality of life (HRQoL) in a Canadian population.
Methods: Time trade-off (TTO) methodology was used to estimate health utilities associated with
hypoglycemic events in a representative sample of the Canadian population. A global analysis conducted
in the United Kingdom, Canada, Germany and Sweden has been published. The present Canadian analysis
focuses on 3 populations: general, type 1 and type 2 diabetes. Using a web-based survey, participants
(>18 years) assessed the utility of 13 different health states (severe, non-severe, daytime and nocturnal
hypoglycemia at different frequencies) using a scale from 1 (perfect health) to 0 (death). The average
disutility value for each type of event was calculated.
Results: Of 2258 participants, 1696 completers were included in the analysis. A non-severe nocturnal
hypoglycemic event was associated with a signiﬁcantly greater disutility than a non-severe daytime
event (0.0076 vs. 0.0056, respectively; p¼0.05), while there was no statistically signiﬁcant difference
between severe nocturnal and severe daytime events (0.0616 vs. 0.0592; p¼0.76). Severe hypogly-
cemia was associated with greater disutility than non-severe hypoglycemia (p<0.0001). Similar trends
were reported in participants with diabetes.
Conclusions: The ﬁndings presented here show that any form of hypoglycemia had a negative impact on
HRQoL in a Canadian population. Nocturnal and/or severe hypoglycemia had a greater negative impact
on HRQoL compared with daytime and/or non-severe events. This highlights the importance of pre-
venting the development and nocturnal manifestation of hypoglycemia in patients with diabetes.
 2014 Canadian Diabetes Association
r é s u m é
Objectif : Le but de cette étude était d’examiner les conséquences de l’hypoglycémie selon la gravité et le
moment de l’apparition sur la qualité de vie liée à la santé (QdVS) d’une population canadienne.
Méthodes : La méthodologie de l’arbitrage temporel a été utilisée pour estimer les états de santé associés
aux événements hypoglycémiques d’un échantillon représentatif de la population canadienne. Une
analyse globale menée au Royaume-Uni, au Canada, en Allemagne et en Suède a été publiée. L’analyse
canadienne actuelle met l’accent sur 3 populations : générale, diabète de type 1 et de type 2. En utilisant
une enquête en ligne, les participants (> 18 ans) ont évalué l’utilité de 13 différents états de santé (grave,
sans gravité, hypoglycémies diurnes et nocturnes à des intensités différentes) en utilisant une échelle de
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S. Harris et al. / Can J Diabetes 38 (2014) 45e52461 (excellente santé) à 0 (mort). La valeur moyenne de la désutilité pour chaque type d’événement a été
calculée.
Résultats : Parmi les 2258 participants, 1696 personnes ayant rempli l’enquête ont été incluses dans
l’analyse. Un événement hypoglycémique nocturne sans gravité a été associé à une désutilité signi-
ﬁcativement plus grande qu’un événement diurne (0,0076 vs 0,0056, respectivement; p ¼ 0,05),
tandis qu’il n’y a pas eu de différence statistiquement signiﬁcative entre les événements nocturnes graves
et les événements diurnes graves (0,0616 vs 0,0592; p ¼ 0,76). L’hypoglycémie grave a été associée à
une désutilité plus grande que l’hypoglycémie sans gravité (p < 0,0001). Des tendances similaires ont été
rapportées chez les participants ayant le diabète.
Conclusions : Les conclusions présentées ici montrent que toute forme d’hypoglycémie a eu des consé-
quences négatives sur la QdVS d’une population canadienne. Les hypoglycémies nocturnes ou graves, ou
nocturnes et graves, ont eu des conséquences négatives plus grandes sur la QdVS comparativement aux
événements diurnes ou sans gravité, ou diurnes et sans gravité. Cela montre l’importance de prévenir le
développement et la manifestation de l’hypoglycémie nocturne chez les patients ayant le diabète.
 2014 Canadian Diabetes Association Open access under CC BY-NC-ND license.Introduction
In 2011, it was estimated that 6.8% of the Canadian population
(>12 years of age) had either type 1 or 2 diabetes (1). Hypoglycemia
is recognized as a limiting factor in the glycemic management of
these individuals and a major cause of morbidity and mortality
(2e4). The incidence of severe hypoglycemia in the Canadian
population with diabetes is estimated to bew1.9 and 2.6 episodes
per patient per year in patients with type 1 and 2 diabetes,
respectively, while the incidence of non-severe hypoglycemia is
estimated to be 102 and 66 episodes per patient per year (5).
Moreover, the incidence of severe hypoglycemia reported during
sleep is estimated to be 0.5 and 0.2 episodes per patient per year in
patients with type 1 and 2 diabetes, respectively (5). Other studies
have shown thatmore than half of severe hypoglycemic events may
occur during the night (6). Nocturnal hypoglycemic episodes are
often asymptomatic due to a reduced autonomic response to
hypoglycemia during sleep (7) and recurring episodes may
contribute toward cognitive impairment, and more seriously to-
ward “dead-in-bed” syndrome (8), which is responsible forw6% of
all deaths in patients with diabetes <40 years of age (9).
Patient-speciﬁc factors that impact health-related quality of life
(HRQoL) are becoming increasingly important in the clinical
decision-making process that underpins the provision of optimal
diabetes treatment (10). Acute hypoglycemia symptoms have sig-
niﬁcant effect on a patient’s overall well-being; however, the total
impact of hypoglycemia needs to account for potential behavioural
changes (avoiding exercise, overeating and reluctance to intensify
therapy), impaired awareness of hypoglycemia (IAH) and fear of
future hypoglycemic events, which are all likely to complicate
glycemic control and diminish treatment effectiveness (11). HRQoL
can be quantiﬁed using health utility values d single summary
measures typically between 0 (death) and 1 (perfect health) that
describe the impact of an intervention or health state on HRQoL
from a patient’s perspective (12). Health utility values can help
quantify the overall impact of hypoglycemia on patients’ HRQoL
with respect to individual events. Although several studies have
measured hypoglycemia utility values, these studies were small in
scale and had various limitations (4,13e15). One study investigated
the HRQoL impact in a Canadian population and showed a utility
loss associated with non-severe hypoglycemia, but did not distin-
guish between diurnal and nocturnal events (16).
The time trade-off (TTO) method, which is a health utility esti-
mation approach that was partly developed in Canada, is recom-
mended by healthcare agencies, such as the Canadian Agency for
Drugs and Technologies in Health (CADTH) and the National
Institute for Health and Clinical Excellence (NICE) in the United
Kingdom. These utility values can be used to calculate quality-
adjusted life-years (QALYs) (17,18) for cost-effectiveness analyses,
and could potentially be used to help optimize diabetes treatmentalgorithms, particularly when utility instruments such as EuroQoL
(EQ-5D) or Health Utilities Index (HUI) are unavailable. The results
from the primary study demonstrate the negative effect of hypo-
glycemia, particularly nocturnal hypoglycemia, on respondents’
HRQoL in a large multinational cohort (19). The primary aim of this
Canadian subanalysis was to assess the impact of hypoglycemia on
HRQoL according to severity and time of onset, using a rigorous
patient-based TTO utility approach in a large Canadian population
of subjects with or without type 1 or 2 diabetes.
Methods
A cross-sectional survey was carried out across a representative
sample of the Canadian general population (18 years of age). This
sample was one of several populations pertaining to a global study,
which included participants from Germany, Sweden, United States
and United Kingdom (19). Participant details were provided
through marketing research company Gfk Custom Research (New
York, NY), where anonymity was preserved throughout the process.
All participants had previously agreed to take part in Internet-
based surveys and several tools (web banners, telephone and per-
sonal interviews) were used to ensure a representative population
was chosen. Participants were offered incentive “points” (a total
corresponding value of 1.50 to 3.00 CAD$) to participate in the
survey, which could then be redeemed against a selection of
commodities. Three speciﬁc study populations were selected:
general population, type 1 and type 2 diabetes. Deciding which is
the most suitable study population (general or patient) for this type
of analysis is a contentious topic, but this decision should be
informed by the downstream application of the results (20e23).
The inclusion of a general population sample is recommended by
CADTH Guidelines for the Economic Evaluation of Health Tech-
nologies (24), given that the general population are the ultimate
payers of the publicly funded health care system. In addition, those
subjects of the general population that had diabetes were identiﬁed
and included in both the general population and diabetes groups.
The full methodology of the global TTO study has been pub-
lished elsewhere (19). Brieﬂy, respondents were asked via an
Internet-based survey (SurveyXact) to “trade-off” a deﬁned portion
of their remaining lifespan for a different health state (see ‘Health
States’ below). This returned a utility value between 0 (death) and 1
(perfect health). To ensure the trade-off values were as accurate and
“real” as possible, the time horizons used in the survey were based
on each respondent’s projected life expectancy (calculated using
WHO life tables (25) and respondent demographics [age and
gender]). The TTO score was determined using the point of indif-
ference (12). To identify the point of indifference with regard to a
TTO question (where both answers are equally acceptable),
respondents were asked the same question repeatedly, varying
only the number of years living in full health each time. This
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starting point of utility of 0.6 and iterative questioning to reduce
the utility value to an interval of 0.05. To prevent bias and inaccu-
rate responses, participants who were willing to trade a large
amount of remaining lifetime for a diabetes health state, or not
willing to trade 1month of lifetime in a health state associated with
diabetes for perfect health, were carefully screened. Participants
were excluded if they failed a TTO “proof-of-understanding”
question or were inconsistent in their responses. Inclusion/exclu-
sion criteria are fully described in (19). To avoid respondent fatigue,
respondents did not evaluate all health states, but were randomly
assigned to: 1) 1 health state of well-controlled diabetes; 2) 1 non-
severe daytime hypoglycemic health state (randomly assigned); 3)
1 non-severe nocturnal hypoglycemic health state (randomly
assigned), and 4) 1 severe hypoglycemic health state (day or night,
randomly assigned).
Participants were asked to provide age, sex, employment/
household/regional details and to complete an EQ-5D survey. Par-
ticipants of the general population who had diabetes were also
asked to provide details regarding the duration of diabetes, medi-
cation, prevalence of hypoglycemic events, awareness of hypogly-
cemic events, A1C and 7-day average blood sugar level. Ethical
approval was obtained from Western University’s Health Sciences
Research Ethics Board (HRSEB), and respondents could choose to
answer the survey in French or English. Responses were translated
twice in parallel for accuracy.Health states
The health states associated with diabetes that participants had
to trade-off against were previously derived via an expert panel,
patient focus groups and an Internet-based validation survey in 247
UK patients with diabetes (26). Thirteen health states were deﬁned,
reﬂecting different hypoglycemic experiences according to episode
frequency, severity and time of onset (Table 1). The descriptions
used for general diabetes, a non-severe nocturnal/diurnal episode
of hypoglycemia and a severe episode of hypoglycemia are pre-
sented in Supplementary Table S1.Statistical analysis
The primary analysis was to estimate the average disutility
associated with each health state deﬁned in Table 1. Unit values per
type of hypoglycemic experience were calculated by taking the
average TTO value for each frequency, weighted according to the
actual distribution of those speciﬁc hypoglycemic event fre-
quencies among the survey participants with diabetes. The average
utility value across respondents was calculated for each health state
and the disutility per hypoglycemic event derived by dividing the
difference between the average utility and the baseline diabetes
state utility by the number of annual events. This ensured that theTable 1
Health states for hypoglycemic events based on frequency, severity and time of onset
Parameter Frequency of hypoglycemic episodes
1
annually
1
quarterly
1
monthly
1
weekly
3
weekly
Baseline diabetes x
Non-severe daytime
events
x x x x
Non-severe nocturnal
events
x x x x
Severe daytime events x x
Severe nocturnal events x x
Total 13 health statesresulting value reﬂected the effect of hypoglycemia alone, and that
there was no confounding inﬂuence from the estimated disutility
associated with having diabetes. Secondary analyses examined
utility differences between non-severe and severe and daytime and
nocturnal hypoglycemic events. In addition, differences between
the general population and diabetes patients were also explored.
Non-parametric bootstrapping was used to simulate standard er-
rors and conﬁdence intervals for the mean TTO values and to test
differences between parameters. The parameter’s distribution is
estimated by repeatedly resampling the original data set with
replacement (27-29). For the present subanalysis, 10 000 iterations
were performed. All statistical analyses were performed using SAS
(v9.2 software: SAS Institue, Cary, NC, USA). All values are presented
as mean and standard error of the mean, unless stated otherwise.
Results
Of 2258 participants from the general Canadian population,
1696 (75.1%) completed the survey correctly and were included in
the ﬁnal analysis. The number and ﬂow of participants for each
studied population (general, type 1 and type 2 diabetes) are pre-
sented in Figure 1. In the general population, the majority of re-
spondents (49.2) were from Ontario, Canada (Table 2) and similar
demographic trends were observed in participants with type 1 or
type 2 diabetes. Background information for each population is
presented in Table 2.
Table 3 presents a comparison of different health states using
“raw” average TTO values. Generally, the reported utility values
were inversely proportional to frequency. Non-severe and severe
nocturnal average TTO values were lower compared with non-
severe and severe daytime values with a few exceptions. These
values were used to derive the average disutility values per hypo-
glycemic event for the 3 study populations (Table 4, Figure 2). In the
general population, disutility values associated with severe hypo-
glycemic events were greater than non-severe values, irrespective
of time of onset (p<0.0001). The mean disutility value per severe
nocturnal event was not signiﬁcantly different from a severe
daytime event (0.0616 [95% conﬁdence interval
(CI) 0.0518, 0.0714] vs. 0.0592 [95% CI 0.0495, 0.0691],
respectively; p¼0.76). The average disutility value per non-severe
nocturnal event was signiﬁcantly greater than the daytime coun-
terpart (0.0076 [95% CI 0.0061, 0.0091] vs. 0.0056 [95%
CI 0.0043, 0.0069], respectively; p¼0.05). Similar trends were
observed in the type 1 and 2 diabetes populations. In comparison to
the general population, participants with type 1 diabetes reported a
signiﬁcantly smaller disutility for a non-severe daytime hypogly-
cemic event (0.0056 [95% CI 0.0043, 0.0069] vs. 0.0030 [95%
CI 0.0009, 0.0054], respectively; p¼0.046) and for a severe
daytime hypoglycemic event (0.0592 [95% CI 0.0495, 0.0691]
vs. 0.0277 [95% CI 0.0088, 0.0499]; p¼0.007). No signiﬁcant
differences were reported between the general population and
participants with type 2 diabetes.
Discussion
Using a TTO approach, the results presented here demonstrate
and quantify, from an individual’s perspective, the negative impact
of different hypoglycemic events on HRQoL in a Canadian popula-
tion. The disutility values (normalized for baseline utility) scored in
the general population and in participants with type 1 or 2 diabetes
were greater for severe hypoglycemic events (regardless of time of
onset) compared to non-severe events, and for nocturnal events
compared to daytime events (regardless of severity). Although
utilities associated with hypoglycemia and its complications have
been estimated previously by other groups using either TTO (16) or
standard gamble methodology (15), these studies did not
Figure 1. Patient ﬂow CONSORT diagram.
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ings provide novel insight into the negative impact of nocturnal/
diurnal hypoglycemia on HRQoL in the general population and in
the population with diabetes; speciﬁcally, a nocturnal non-severe
hypoglycemic event carried a signiﬁcantly greater disutility than
its diurnal counterpart, and although not signiﬁcant, a similar trend
was also observed for nocturnal severe events. By contrast, using a
retrospective survey (n¼861) and generic utility estimates (EQ-5D
and SF-36), Davis et al demonstrated that nocturnal hypoglycemia
had less of an effect on HRQoL during the 3 months before un-
dertaking the survey; however, the analysis lacked statistical rigour
as the overall population in this category was small (n¼5 for type 1,
n¼2 for type 2) (4).
Interestingly, differences in the average disutility for diurnal
hypoglycemia were observed between the general population and
the population with type 1 diabetes; however, no differences were
reported in comparison with the population with type 2 diabetes.
The reasons underpinning these ﬁndings are not clear; however,
studies have identiﬁed differences in perspective between pop-
ulations with type 1 and 2 diabetes in terms of the factors that
cumulatively affect HRQoL. Solli et al showed that ischemic heart
disease and social limitations had a greater negative impact on
HRQoL in patients with type 1 diabetes, whereas fear of hypogly-
cemia and work limitations had a greater impact on patients with
type 2 diabetes (30). The small number of individuals with diabetes
may be considered a limitation of the analysis; however, sample
size is aligned with other quality-of-life utility studies (15,16,31). It
should also be noted that the study was not designed, and therefore
not necessarily powered to resolve differences between groups.The ﬁndings presented here are in general agreement with the
results of the global TTO parent study (19); although the average
utility value associated with baseline diabetes was lower in the
Canadian population compared with the global population (0.819
vs. 0.844, respectively). The reason for this difference is unclear;
however, the TTO utility for baseline diabetes presented here was
also lower compared with a distinct Canadian cohort (0.88) (16).
In the clinical management of diabetes, it is important to
consider the overall impact of hypoglycemic events on patients’
HRQoL as they may result in fear of future events and behavioural
changes that may impinge upon adherence to treatment, thus
compromising glycemic control and patient well-being. In a typical
clinical trial, safety endpoints may only account for acute hypo-
glycemic symptoms while overlooking the total negative impact of
a hypoglycemic event on the psychopharmacological and psycho-
social functioning of an individual or cohort. Studies show that
patients with type 1 or 2 diabetes who experience a non-severe
daytime hypoglycemic event tend to monitor their glucose more
carefully and reduce their normal number of doses or units of in-
sulin (32). Similar behaviour has also been associated with
nocturnal non-severe events, in addition to a reported increase in
tiredness, sleeping difﬁculties and absenteeism fromwork (33). In a
Canadian study, 37.8% and 29.9% of patients with type 1 or 2 dia-
betes, respectively, reported an increase in fear of future hypogly-
cemia following a non-severe hypoglycemic event, while a larger
proportion of patients (63.6% and 84.2%, respectively) reported an
increase in fear following a severe hypoglycemic event (5).
Furthermore, the fear and risk of severe hypoglycemia may be
compounded if a patient is prone to IAH (34e36); a clinically
Table 2
Respondent proﬁle for Canada
Characteristics General
population,
n (%)
Type 1
diabetes,
n (%)
Type 2
diabetes,
n (%)
Gender
Male 874 (52) 51 (48) 171 (52)
Female 822 (48) 55 (52) 160 (48)
Mean age 46 39 55
Mean EQ5D score 0.81 0.75 0.71
Occupation
In full-time education 93 (5) 10 (9) 8 (2)
Employed/self-employed 794 (47) 51 (48) 103 (31)
Unpaid work for a business
you or a relative owns
19 (1) 4 (4) 6 (2)
Looking for paid work/government
training scheme
85 (5) 3 (3) 16 (5)
Permanently unable to work due to
long-term sickness/disability
124 (7) 13 (12) 61 (18)
Retired 282 (17) 13 (12) 96 (29)
Looking after home or family 219 (13) 9 (8) 29 (9)
Other 80 (5) 3 (3) 12 (4)
Household status
1 adult, no children 331 (20) 20 (19) 78 (24)
1 adult, children 85 (5) 3 (3) 13 (4)
2 adults, no children 617 (36) 32 (30) 153 (46)
2 adults, children 436 (26) 36 (34) 50 (15)
3 adults, no children 120 (7) 8 (8) 20 (6)
3 adults, children 35 (2) 4 (4) 6 (2)
Other 72 (4) 3 (3) 11 (3)
Has a doctor told you that you have diabetes?
Yes 197 (12)* N/A N/A
No 1499 (88) N/A N/A
Number of individuals with diabetes that have experienced a hypoglycemic
event
Non-severe daytime 102 (52) 66 (62) 175 (53)
Non-severe nocturnal 59 (30) 46 (43) 93 (28)
Severe daytime 25 (13) 26 (25) 46 (14)
Severe nocturnal 25 (13) 22 (21) 33 (10)
Regional distribution
Alberta 156 (9.2) 5 (4.7) 33 (10)
British Columbia 226 (13.3) 14 (13.2) 44 (13.3)
Manitoba 82 (4.8) 1 (0.9) 14 (4.2)
New Brunswick 64 (3.8) 1 (0.9) 10 (3)
Newfoundland and Labrador 44 (2.6) 1 (0.9) 9 (2.7)
Northwest Territories 1 (0.06) 0 (0.0) 0 (0.0)
Nova Scotia 78 (4.6) 2 (1.9) 13 (3.9)
Nunavut 1 (0.06) 0 (0.0) 0 (0.0)
Ontario 836 (49.3) 59 (55.7) 159 (48)
Prince Edward Island 8 (0.5) 0 (0.0) 0 (0.0)
Québec 150 (8.8) 22 (20.8) 36 (10.9)
Saskatchewan 48 (2.8) 1 (0.9) 12 (3.6)
Yukon 2 (0.1) 0 (0.0) 1 (0.3)
* The distribution of responses in this subpopulation were Type 1 (n¼24), Type 2
(n¼155), Other type (n¼9), and Don’t know (n¼9).
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onset of a hypoglycemic episode is reduced or absent.
The reported utility estimates for nocturnal and diurnal
hypoglycemic events may also be of value in terms of improvingTable 3
Average time trade-off utility values for health states (95% conﬁdence intervals, bootstra
Health state Frequency
1 annually 1 quar
Baseline diabetes 0.819 [0.807, 0.830] (n¼1562) e e
Non-severe daytime e e 0.775
(n¼38
Non-severe nocturnal e e 0.788
(n¼40
Severe daytime e 0.741 [0.714, 0.768]
(n¼351)
0.724
(n¼38
Severe nocturnal e 0.732 [0.703, 0.758]
(n¼376)
0.711
(n¼38treatment algorithms for hypoglycemia, thus potentially
providing further direction for the overall management of dia-
betes. The current Canadian Diabetes Association (CDA) algorithm
recommends ﬁxed amounts of carbohydrate depending on the
degree of hypoglycemia and the conscious state of the individual;
however, the algorithm does not contain guidance based on the
time of onset of hypoglycemia (37). Nevertheless, it remains un-
clear how large a utility difference needs to be on the TTO scale to
be considered clinically important. These intervals are referred to
as “minimal important differences” (MID) and are central to the
clinical interpretation of trials that use patient-based HRQoL
utility outcomes. MID can be deﬁned as “the smallest difference in
score in the domain of interest which patients perceive as beneﬁcial
and which would mandate, in the absence of troublesome side effects
and excessive cost, a change in the patient’s management” (38). A
recent study provided MID estimates (standard deviation) for
several scales, including the HUI2 (0.0450.039), HUI3
(0.0320.027), EQ-5D (US algorithm, 0.0400.026), EQ-5D (UK
algorithm, 0.0820.032) and SF-6D (0.0270.028) (39). Drum-
mond reported a MID in utilities of 0.03 for the 15D instrument
and the Health Utility Index, with the elaboration that differences
as little as 0.01 may be meaningful and important in some con-
texts (40). Although the MID for TTO utility values has not been
determined and the differences in the calculated disutilities per
hypoglycemic event presented here may appear negligible, it is
important to note that when considering the cumulative disutility
per hypoglycemic event over a speciﬁc time period (e.g. 1 year),
the overall impact on HRQoL may be substantial. Furthermore,
with the TTO approach, all differences are important as the re-
spondents trade-off something valuable to avoid them.
In clinical practice, the phenomenon of “ﬁrst being worst” is
generally accepted; i.e. the effect each individual hypoglycemic event
has onHRQoLdiminishes as the frequencyof events increases and the
patient adapts to take these events into account during their daily
routine. In health-economic terms, this is referred to as diminishing
marginal disutility. Interestingly, the reported degree of disutility
appeared to increase with increasing frequency of non-severe
hypoglycemic events in this study, regardless of the time of onset.
This may reﬂect a coping mechanism (learning to live with hypo-
glycemia), a maximum limit for trading off remaining lifetime or the
nature of the studywhere some respondentsmay paymore attention
to the health state descriptions than the actual frequencies.
TTO methodology is a well-recognized health utility estimation
approach (12,41) and is advocated by health technology assessment
bodies, such as the Canadian Agency for Drugs and Technologies in
Health and National Institute for Clinical Excellence for the gener-
ation of QALY ﬁgures (12,17,18,42). Indeed, the presented data are
representative of the Canadian population and thus provides highly
relevant and local data for Canadian health technology assessments
and health economic modeling of new and existing diabetes
treatments. Although TTO analysis has been used by another group
to study the utility values for non-severe hypoglycemia (16), otherpped) in the Canadian general population
terly 1 monthly 1 weekly 3 weekly
e e e
[0.750, 0.801]
2)
0.772 [0.746, 0.797]
(n¼373)
0.784 [0.760, 0.807]
(n¼396)
0.745 [0.720, 0.770]
(n¼389)
[0.765, 0.811]
4)
0.769 [0.742, 0.796]
(n¼362)
0.754 [0.731, 0.777]
(n¼394)
0.713 [0.685, 0.741]
(n¼356)
[0.696, 0.747]
0)
e e e
[0.686, 0.739]
5)
e e e
Table 4
Average time trade-off utility values per hypoglycemic event for each health state
General population Type 1 diabetes Type 2 diabetes
n Utility [95% CI] n Utility [95% CI] n Utility [95% CI]
Diabetes with no events 1562 0.8186 [0.8075, 0.8296] 99 0.8314 [0.7916, 0.8679] 306 0.8631 [0.8413, 0.8842]
Non-severe daytime event 1512 0.0056 [0.0043, 0.0069] 98 0.0030 [0.0009, 0.0054] 295 0.0028 [0.0001, 0.0057]
Non-severe nocturnal event 1487 0.0076 [0.0061, 0.0091] 96 0.0052 [0.0027, 0.0082] 295 0.0076 [0.0046, 0.0109]
Severe daytime event 714 0.0592 [0.0495, 0.0691] 46 -0.0277 [0.0088, 0.0499] 154 0.0726 [0.0493, 0.0983]
Severe nocturnal event 744 0.0616 [0.0518, 0.0714] 50 0.0657 [0.0212, 0.1219] 131 0.0826 [0.0568, 0.1103]
CI, conﬁdence interval.
S. Harris et al. / Can J Diabetes 38 (2014) 45e5250generic utility estimation techniques, such as EQ-5D (4,13e15,43)
and SF-36 (4), are more regularly encountered. Generic tech-
niques, however, are typically considered less sensitive compared
with TTO methods. The EQ-5D score system, for example, has been
suggested to lack responsiveness for use in QoL studies in patients
with diabetes (25,44). An advantage of using a TTO approach is that
respondents implicitly express the importance of an improved
health state by trading a deﬁned length of life for a deﬁned
improvement in quality of life. Another strength of this study was
the use of trade-off questions that were based on the age-
dependent life expectancy of each individual respondent, as it
helped to avoid some of the disadvantages of using an artiﬁcially
ﬁxed time horizon (45) and thus increased the relevance of the
trade-offs to the respondents. This, in turn, would be expected toFigure 2. Disutility values of non-seprovide more reliable utility estimates and has been applied to
similar studies by other groups (46,47).
The web-based nature of the survey did not allow for the
calculation of traditional non-response rates and may have also
given rise to several limitations, such as a lack of supervision and
guidance for participants during the survey, and a selection bias
towards computer/Internet users. The survey design did not allow
for the measurement of intra-individual variation as each individ-
ual was randomly assigned to evaluate a different set of the studied
health states. This design was implemented to prevent respondent
fatigue. It is also important to highlight that the majority of re-
spondents in this study had to pass judgment on different health
states associated with diabetes without ever previously experi-
encing diabetes. However, although it remains a contentiousvere and severe hypoglycemia.
S. Harris et al. / Can J Diabetes 38 (2014) 45e52 51subject, studies have shown that there are no signiﬁcant differences
between the general population and people who actually experi-
ence illness in the qualiﬁcation of a relevant disease health state
(48,49). Furthermore, the CADTH prefers the use of the general
population when assessing utilities in the reference case, as ulti-
mately they are the payers of the public health care system and
potential patients, while the use of patient preferences is suggested
for additional sensitivity analyses (24).
The presented analysis provides a unique utility evaluation,
using TTO methodology, of severe compared with non-severe
hypoglycemic events according to time of onset in a Canadian
cohort, providing a measure of the respective contributions made
by each distinct hypoglycemic health state to patient HRQoL. The
ﬁndings showed that nocturnal and/or severe hypoglycemia had a
greater negative impact on respondents’ HRQoL compared with
diurnal and/or non-severe events, thus highlighting the importance
of preventing the development and nocturnal manifestation of
hypoglycemia in the overall management of diabetes.
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